Innovating New Treatments for People with Ultra-rare Bone Disorders and Other Diseases

A Commitment to Patients

The patients we serve are at the forefront of everything we do. We work closely with physicians, researchers and affected families in the interest of the larger patient and medical communities.

Learn More

Our Trials

We are currently enrolling patients in our Phase 2 MO-Ped Trial for palovarotene in multiple osteochondromas (MO), the first-ever trial for patients with this disease.

Learn More

Our Clinical Programs

A 2011 paper published in Nature Medicine by the team of Dr. Maurizio Pacifici showed that palovarotene, a retinoic acid receptor gamma (RARγ) selective agonist, potently inhibited new bone formation in animal models of FOP. Clementia is developing palovarotene for the treatment of people with fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and dry eye disease.

Learn More

Fibrodysplasia Ossificans Progressiva

FOP is an ultra-rare, genetic, chronic disease that causes bone growth in muscles, tendons and soft tissue and leaves most affected individuals confined to a wheelchair by the third decade of their life.

Learn About FOP

Multiple Osteochondromas

MO, also called multiple hereditary exostoses (MHE or HME), is an ultra-rare genetic musculoskeletal condition in which multiple benign tumors, also known as osteochondromas (OCs), develop on bones.

Learn About MO

Our CEO, Clarissa Desjardins, Ph.D., was recognized as the recipient of the 2018 Bloom Burton Award, which honors an individual who has made the greatest impact in Canada's innovative healthcare industry.